AFRICAN AMERICAN STUDY OF KIDNEY DISEASE AND HYPERTENSIO

非裔美国人的肾脏疾病和高血压研究

• 批准号: 6177114
• 负责人: SHAUL G MASSRY
• 金额: $ 80.19万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-07-01 至 2002-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6177114
• 关键词: ACE inhibitors; African American; antihypertensive agents; beta antiadrenergic agent; blood pressure; calcium channel blockers; cardiovascular disorder chemotherapy; cardiovascular pharmacology; chronic renal failure; clinical trials; cooperative study; disease /disorder proneness /risk; drug screening /evaluation; glomerular filtration rate; human subject; human therapy evaluation; hypertension; kidney function

DESCRIPTION (taken directly from the application) Evidence exists suggesting that the incidence of hypertension in African Americans (AA) is markedly and significantly higher than in whites, and that the kidneys of AA are more susceptible to hypertension; and for any given level of blood pressure elevation, the renal circulation in AA may be subjected to a greater injury. Thus, the incidence of end stage renal disease due to hypertension in AA is several times higher than in whites. Indeed every day in Los Angeles, one new AA begins dialysis treatment for renal failure due to hypertension. It is not known whether stricter control of hypertension (MAP less than 92 mmHg) is superior to the usual control of hypertension (MAP 102-107mmHg) in protecting renal function in AA. Further, other data suggest that certain antihypertensive drugs such as angiotensin converting enzyme inhibitors (ACEI) or calcium channel blockers (CCB) may retard progression of renal failure better than other medications. Thus, a controlled study examining the efficacy of these drugs and the impact of two levels of blood pressure control on the progression of renal failure in hypertension AA is needed. The proposed research is a part of a multicenter, prospective, double masked randomized clinical trial examining the effect of three drug regimens (ACEI, CCB and B-blockers) and two different levels of MAP control (less than 92 versus 102-107 mmHg). Thus, the study will follow a three by two factorial design. The outcome of the study will estimate the changes in GFR in a fixed time period among the three treatment arms and the two levels of blood pressure control. The University of Southern California (USC), Martin Luther King-Drew Medical Center (MLK) and Harbor General Hospital-UCLA (HGH) are three major institutions which provide care for renal diseases and hypertension among the one million AA living in Los Angeles. These three institutions have teamed in a consortium during the pilot study of AASK and have been successful in their recruitment efforts. We will continue this consortium for the full scale study and will use our expertise, experience and commitment to bring to successful fruition our part in this multicenter Study.

描述（直接取自应用程序） 有证据表明，非洲高血压的发病率 美国人（AA）明显高于白人， AA的肾脏更容易患高血压;对于任何 考虑到血压升高的水平，AA患者的肾循环可能 受到更大的伤害。 因此，终末期肾病的发生率 AA中由于高血压引起的疾病是白人的几倍。 事实上，在洛杉矶，每天都有一个新的AA开始透析治疗， 由于高血压引起的肾衰竭。 目前尚不清楚是否更严格 对高血压的控制（MAP低于92 mmHg）优于常规治疗（上级） 控制高血压（MAP 102- 107 mmHg），保护肾功能 在戒酒协会。 此外，其他数据表明，某些抗高血压药物 例如血管紧张素转化酶抑制剂（ACEI）或钙 通道阻滞剂（CCB）可更好地延缓肾功能衰竭的进展 比其他药物。 因此，一项对照研究检查了 这些药物和两个水平的血压控制的影响 对高血压肾衰竭的进展需要AA。 这项研究是一项多中心、前瞻性、双重 一项检查三种药物疗效的盲法随机临床试验 方案（ACEI，CCB和B受体阻滞剂）和两种不同水平的MAP 对照组（小于92与102-107 mmHg）。 因此，本研究将遵循 三乘二析因设计 研究结果将估计 三个治疗组在固定时间段内GFR的变化 以及两个级别的血压控制。 南加州大学（USC），马丁·路德·金-德鲁 医疗中心（MLK）和加州大学洛杉矶分校海港总医院（HGH）是三个 为肾病和高血压提供护理的主要机构 在洛杉矶的一百万匿名戒酒者中。这三个机构 在AASK的试点研究期间， 成功地进行了招聘。 我们将继续这一 联合体进行全面研究，并将利用我们的专业知识， 经验和承诺，使我们的一部分， 这项多中心研究。